InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.180

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$108 Cleansing Notice and Appendix 3B 13 Dec 2019 4:51PM $3.050 $0.180 fallen by 94.10%
$108 Paradigm End of Calendar Year Update 12 Dec 2019 8:21AM $3.130 $0.180 fallen by 94.25%
$108 Cleansing Notice 4 Dec 2019 8:43AM $3.610 $0.180 fallen by 95.01%
$108 Appendix 3B 4 Dec 2019 8:41AM $3.610 $0.180 fallen by 95.01%
$108 Cleansing Notice and Appendix 3B 25 Nov 2019 4:04PM $3.670 $0.180 fallen by 95.10%
$108 Change of Director's Interest Notice 19 Nov 2019 4:21PM $3.750 $0.180 fallen by 95.20%
$108 Change in substantial holding 14 Nov 2019 8:11PM $2.980 $0.180 fallen by 93.96%
$108 Change of Director's Interest Notice 14 Nov 2019 8:05PM $2.980 $0.180 fallen by 93.96%
$108 Cleansing Notice and Appendix 3B 11 Nov 2019 11:27AM $3.030 $0.180 fallen by 94.06%
$108 Results of Meeting 7 Nov 2019 6:05PM $2.930 $0.180 fallen by 93.86%
$108 Paradigm AGM Presentation 7 Nov 2019 10:47AM $2.800 $0.180 fallen by 93.57%
$108 Quarterly Update and Appendix 4C - quarterly 31 Oct 2019 10:11AM $2.990 $0.180 fallen by 93.98%
$108 PARADIGM PROVIDES REGULATORY FILING UPDATE 25 Oct 2019 8:21AM $2.670 $0.180 fallen by 93.26%
$108 Cleansing Notice and Appendix 3B 22 Oct 2019 5:03PM $2.720 $0.180 fallen by 93.38%
$108 Notice of Annual General Meeting/Proxy Form 4 Oct 2019 11:16AM $2.950 $0.180 fallen by 93.90%
$108 Cleansing Notice and Appendix 3B 1 Oct 2019 4:20PM $2.960 $0.180 fallen by 93.92%
$108 Osteoarthritis pain reduced by Paradigms Zilosul (PPS) 30 Sep 2019 8:13AM $2.530 $0.180 fallen by 92.89%
$108 Cleansing Notice and Appendix 3B 24 Sep 2019 5:13PM $2.520 $0.180 fallen by 92.86%
$108 Cleansing Notice and Appendix 3B 17 Sep 2019 11:24AM $2.110 $0.180 fallen by 91.47%
$108 Cleansing Notice and Appendix 3B 12 Sep 2019 4:07PM $2.030 $0.180 fallen by 91.13%
$108 PAR Expanded Access IND Cleared by US FDA 10 Sep 2019 10:32AM $2.120 $0.180 fallen by 91.51%
$108 Appendix 4G and 2019 Corporate Governance Statement 30 Aug 2019 12:51PM $1.623 $0.180 fallen by 88.91%
$108 Appendix 4E and 2019 Annual Report 30 Aug 2019 12:50PM $1.623 $0.180 fallen by 88.91%
$108 PARs drug reduces cartilage degradation in subjects with OA 29 Aug 2019 8:27AM $1.440 $0.180 fallen by 87.50%
$108 PARADIGM FILES FIRST IND WITH US FDA 7 Aug 2019 9:37AM $1.370 $0.180 fallen by 86.86%

476 - 500 of 721 results

Page 20 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.